These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 5311767)

  • 1. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 2. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 6. [The excretion of vanilmandelic acid, vanillic acid, homovanillic acid and 5-hydroxyindoleacetic acid by urine in smokers and non-smokers].
    Schmid E; Tautz NA; Bauersachs E; Krautheim J
    Arzneimittelforschung; 1968 Jul; 18(7):819-21. PubMed ID: 5755826
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 8. Imipramine-mediated effects on levodopa metabolism in man.
    Messiha FS; Morgan JP
    Biochem Pharmacol; 1974 May; 23(10):1503-7. PubMed ID: 4847533
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical, electroencephalographic and biochemical aspects of the 1-dopa effect].
    Bente D; Stoerger R; Tautz NA
    Arzneimittelforschung; 1966 Feb; 16(2):265-7. PubMed ID: 6013814
    [No Abstract]   [Full Text] [Related]  

  • 10. Brain dopamine and noradrenaline in 3 Parkinsonians deceased during L-dopa treatment.
    Buscaino GA; Jori A; Campanella G
    Acta Neurol (Napoli); 1972; 27(6):537-44. PubMed ID: 4651485
    [No Abstract]   [Full Text] [Related]  

  • 11. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 13. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary monoamine metabolites in children with minimal brain dysfunction.
    Wender PH; Epstein RS; Kopin IJ; Gordon EK
    Am J Psychiatry; 1971 Apr; 127(10):1411-5. PubMed ID: 5549938
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic patterns and clinical response to levedopa therapy in Parkinson's disease.
    Messiha FS; Knopp W
    Clin Pharmacol Ther; 1973; 14(4):565-71. PubMed ID: 4541856
    [No Abstract]   [Full Text] [Related]  

  • 17. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cerebral and peripheral consumption of L-5-HTP in patients with manic, depressive or psychotic syndromes].
    Gaillard JM; Eisenring JJ; Tissot R
    Encephale; 1973; 62(5):395-407. PubMed ID: 4546593
    [No Abstract]   [Full Text] [Related]  

  • 19. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 20. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.